Telix (ASX:TLX) share price jumps 7% on major Merck collaboration

Telix shares are nearing a record high on Wednesday…

| More on:
active person star jumping amid city landscape

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Telix Pharmaceuticals Ltd (ASX: TLX) share price has been a very strong performer on Wednesday.

The molecularly targeted radiation (MTR) focused biopharmaceutical company's shares have jumped 7% to $6.53 today.

This means the Telix share price is now trading close to its record high of $6.65.

Why is the Telix share price storming higher?

The Telix share price is being bid higher by investors today following the release of a promising announcement this morning.

According to the release, the company has entered into a pan-cancer clinical collaboration with pharmaceutical giant Merck. This builds on the success of a strategic research collaboration agreement between the two companies in 2019.

The release explains that the agreement will see the two parties conduct combination studies with one of Merck's investigational proprietary DNA Damage Response Inhibitor (DDRi) molecules in combination with each of Telix's TLX591 and TLX250 MTR therapeutic programs.

TLX591 and TLX250 are late-stage products in development for prostate and renal cancer therapy, respectively. The collaboration will investigate the synergy of these investigational assets with Merck's DDRi compound across a wide variety of oncology indications.

"The vanguard of nuclear medicine and oncology"

Telix's CEO, Dr. Christian Behrenbruch, appeared to be very pleased with the agreement.

He said: "This collaboration represents the vanguard of nuclear medicine and oncology, and we are excited by the level of new data and intellectual property already generated, which is highly supportive of clinical translation."

"Pre-clinical studies provide evidence that the combined effect of Merck's DDRi compound with Telix's MTR candidates has potential to significantly impact cancer by improving efficacy and reducing the required radiation dose for tumour reduction and remission, compared to MTR only," Dr Behrenbruch added.

Today's gain means the Telix share price is smashing the market in 2021 and now up over 60% year to date.

Motley Fool contributor James Mickleboro owns shares of TELIXPHARM DEF SET. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

A man looking at his laptop and thinking.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors were pulled back down to earth this Tuesday.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Share Gainers

Why EML Payments, Gentrack, Regis, and Resimac shares are racing higher

These shares are outperforming on Tuesday. What's going on?

Read more »

A young woman smiles as she rides a zip line high above the trees.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors kicked off the trading week in style today.

Read more »

Person pointing at an increasing blue graph which represents a rising share price.
Share Gainers

Why Liberty, Lovisa, Novonix, and SG Fleet shares are storming higher today

These shares are starting the week strongly. But why? Let's find out.

Read more »

Young girl drinking milk showing off muscles.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a great end to the trading week for ASX investors today.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Share Gainers

3 ASX 200 stocks smashing the benchmark this week

These three ASX 200 stocks are leading the charge this week. Here’s how.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Share Gainers

Why A2 Milk, EOS, GQG, and Mineral Resources shares are racing higher today

These shares are ending the week strongly. But why?

Read more »

A man wearing a red jacket and mountain hiking clothes stands at the top of a mountain peak and looks out over countless mountain ranges.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another disappointing day for ASX investors this Thursday.

Read more »